69 related articles for article (PubMed ID: 20158081)
1. [Structural insights of PPARgamma].
Kato S; Takada I
Nihon Rinsho; 2010 Feb; 68(2):176-9. PubMed ID: 20158081
[No Abstract] [Full Text] [Related]
2. Insights into PPARgamma from structures with endogenous and covalently bound ligands.
Nettles KW
Nat Struct Mol Biol; 2008 Sep; 15(9):893-5. PubMed ID: 18769464
[No Abstract] [Full Text] [Related]
3. Identification of novel PPARalpha ligands by the structural modification of a PPARgamma ligand.
Usui S; Fujieda H; Suzuki T; Yoshida N; Nakagawa H; Miyata N
Bioorg Med Chem Lett; 2006 Jun; 16(12):3249-54. PubMed ID: 16621530
[TBL] [Abstract][Full Text] [Related]
4. Structural insight into PPARgamma activation through covalent modification with endogenous fatty acids.
Waku T; Shiraki T; Oyama T; Fujimoto Y; Maebara K; Kamiya N; Jingami H; Morikawa K
J Mol Biol; 2009 Jan; 385(1):188-99. PubMed ID: 18977231
[TBL] [Abstract][Full Text] [Related]
5. Atomic structure of mutant PPARgamma LBD complexed with 15d-PGJ2: novel modulation mechanism of PPARgamma/RXRalpha function by covalently bound ligands.
Waku T; Shiraki T; Oyama T; Morikawa K
FEBS Lett; 2009 Jan; 583(2):320-4. PubMed ID: 19101554
[TBL] [Abstract][Full Text] [Related]
6. Indenone derivatives: a novel template for peroxisome proliferator-activated receptor gamma (PPARgamma) agonists.
Ahn JH; Shin MS; Jung SH; Kang SK; Kim KR; Rhee SD; Jung WH; Yang SD; Kim SJ; Woo JR; Lee JH; Cheon HG; Kim SS
J Med Chem; 2006 Jul; 49(15):4781-4. PubMed ID: 16854085
[TBL] [Abstract][Full Text] [Related]
7. Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies.
Mahindroo N; Wang CC; Liao CC; Huang CF; Lu IL; Lien TW; Peng YH; Huang WJ; Lin YT; Hsu MC; Lin CH; Tsai CH; Hsu JT; Chen X; Lyu PC; Chao YS; Wu SY; Hsieh HP
J Med Chem; 2006 Feb; 49(3):1212-6. PubMed ID: 16451087
[TBL] [Abstract][Full Text] [Related]
8. [Activation mechanism of PPARgamma by its endogenous ligands].
Shiraki T; Kamiya N; Jingami H
Tanpakushitsu Kakusan Koso; 2005 Nov; 50(13):1660-5. PubMed ID: 16277244
[No Abstract] [Full Text] [Related]
9. Structural requirement for PPARgamma binding revealed by a meta analysis of holo-crystal structures.
Nascimento AS
Biochimie; 2010 May; 92(5):499-506. PubMed ID: 20138109
[TBL] [Abstract][Full Text] [Related]
10. Construction of a virtual combinatorial library using SMILES strings to discover potential structure-diverse PPAR modulators.
Liao C; Liu B; Shi L; Zhou J; Lu XP
Eur J Med Chem; 2005 Jul; 40(7):632-40. PubMed ID: 15935898
[TBL] [Abstract][Full Text] [Related]
11. Structure-based de novo design, synthesis, and biological evaluation of the indole-based PPARgamma ligands (I).
Dong X; Zhang Z; Wen R; Shen J; Shen X; Jiang H
Bioorg Med Chem Lett; 2006 Nov; 16(22):5913-6. PubMed ID: 17010604
[TBL] [Abstract][Full Text] [Related]
12. The synthesis of tethered ligand dimers for PPARgamma-RXR protein heterodimers.
Mohler DL; Shen G
Org Biomol Chem; 2006 Jun; 4(11):2082-7. PubMed ID: 16729120
[TBL] [Abstract][Full Text] [Related]
13. Rational discovery of a novel interface for a coactivator in the peroxisome proliferator-activated receptor gamma: theoretical implications of impairment in type 2 diabetes mellitus.
Shiraki T; Kodama TS; Jingami H; Kamiya N
Proteins; 2005 Feb; 58(2):418-25. PubMed ID: 15558556
[TBL] [Abstract][Full Text] [Related]
14. Partial agonists activate PPARgamma using a helix 12 independent mechanism.
Bruning JB; Chalmers MJ; Prasad S; Busby SA; Kamenecka TM; He Y; Nettles KW; Griffin PR
Structure; 2007 Oct; 15(10):1258-71. PubMed ID: 17937915
[TBL] [Abstract][Full Text] [Related]
15. NSAIDs revisited: putative molecular basis of their interactions with peroxisome proliferator-activated gamma receptor (PPARgamma).
Romeiro NC; Sant'Anna CM; Lima LM; Fraga CA; Barreiro EJ
Eur J Med Chem; 2008 Sep; 43(9):1918-25. PubMed ID: 18222570
[TBL] [Abstract][Full Text] [Related]
16. Computational screening of phthalate monoesters for binding to PPARgamma.
Kaya T; Mohr SC; Waxman DJ; Vajda S
Chem Res Toxicol; 2006 Aug; 19(8):999-1009. PubMed ID: 16918238
[TBL] [Abstract][Full Text] [Related]
17. Functional implications of genetic variation in human PPARgamma.
Jeninga EH; Gurnell M; Kalkhoven E
Trends Endocrinol Metab; 2009 Oct; 20(8):380-7. PubMed ID: 19748282
[TBL] [Abstract][Full Text] [Related]
18. Continuous nucleocytoplasmic shuttling underlies transcriptional activation of PPARgamma by FABP4.
Ayers SD; Nedrow KL; Gillilan RE; Noy N
Biochemistry; 2007 Jun; 46(23):6744-52. PubMed ID: 17516629
[TBL] [Abstract][Full Text] [Related]
19. Structure-based drug design of a novel family of PPARgamma partial agonists: virtual screening, X-ray crystallography, and in vitro/in vivo biological activities.
Lu IL; Huang CF; Peng YH; Lin YT; Hsieh HP; Chen CT; Lien TW; Lee HJ; Mahindroo N; Prakash E; Yueh A; Chen HY; Goparaju CM; Chen X; Liao CC; Chao YS; Hsu JT; Wu SY
J Med Chem; 2006 May; 49(9):2703-12. PubMed ID: 16640330
[TBL] [Abstract][Full Text] [Related]
20. Strategies for the labeling of halogen-substituted peroxisome proliferator-activated receptor gamma ligands: potential positron emission tomography and single photon emission computed tomography imaging agents.
Lee BC; Lee KC; Lee H; Mach RH; Katzenellenbogen JA
Bioconjug Chem; 2007; 18(2):514-23. PubMed ID: 17315977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
